Front Row Advisors’s Pacira BioSciences PCRX Stock Holding History

Front Row Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-73	Closed	-$3K	–	939
2022 Q4	$3K	Hold	73	–	–	﹤0.01%	746
2022 Q3	$4K	Hold	73	–	–	﹤0.01%	713
2022 Q2	$4K	Hold	73	–	–	﹤0.01%	729
2022 Q1	$6K	Hold	73	–	–	﹤0.01%	679
2021 Q4	$4K	Hold	73	–	–	﹤0.01%	799
2021 Q3	$4K	Hold	73	–	–	﹤0.01%	786
2021 Q2	$4K	Hold	73	–	–	﹤0.01%	788
2021 Q1	$5K	Hold	73	–	–	﹤0.01%	738
2020 Q4	$4K	Hold	73	–	–	﹤0.01%	741
2020 Q3	$5K	Hold	73	–	–	﹤0.01%	696
2020 Q2	$4K	Hold	73	–	–	﹤0.01%	705
2020 Q1	$3K	Hold	73	–	–	﹤0.01%	754
2019 Q4	$3K	Hold	73	–	–	﹤0.01%	733
2019 Q3	$3K	Hold	73	–	–	﹤0.01%	738
2019 Q2	$3K	Hold	73	–	–	﹤0.01%	759
2019 Q1	$3K	Hold	73	–	–	﹤0.01%	758
2018 Q4	$3K	Hold	73	–	–	﹤0.01%	704
2018 Q3	$3	Hold	73	–	–	﹤0.01%	713
2018 Q2	$3	Hold	73	–	–	﹤0.01%	769
2018 Q1	$2K	Hold	73	–	–	﹤0.01%	804
2017 Q4	$3K	Buy	+73	New	+$2.89K	﹤0.01%	624

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Front Row Advisors's PCRX Position: Q1 2023 in Review

Front Row Advisors sold out of Pacira BioSciences (PCRX) in Q1 2023, closing a stake of 73 shares — an estimated $3K sold.

Front Row Advisors first reported a position in PCRX in Q4 2017 and held it in 21 quarters. The position peaked at $6K in Q1 2022. 267 funds tracked by Wall St. Rank hold PCRX as of Q1 2023.

Front Row Advisors reported no remaining Pacira BioSciences position as of Q1 2023 after selling out during the quarter.
Front Row Advisors sold 73 Pacira BioSciences shares in Q1 2023, an estimated $3K.
Front Row Advisors first reported a position in Pacira BioSciences in Q4 2017 and held it in 21 quarters.
Front Row Advisors's Pacira BioSciences position peaked at $6K in Q1 2022.
267 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2023.

Based on Front Row Advisors's 13F filing for Q1 2023, filed 15 May 2023.